Getein Biotech Inc. (stock code: 603387), established in 2002 and headquartered in Nanjing, China, is a fully integrated in vitro diagnostic (IVD) enterprise specializing in research, development, manufacturing, and global distribution of innovative diagnostic test kits and analytical medical devices. Situated within a 10.5 km² science park equipped with advanced R&D and production facilities, the company develops technologies across point-of-care testing (POCT), clinical chemistry, chemiluminescent assays, hematology, coagulation, urinalysis, molecular diagnostics, and raw materials for diagnostic reagents.
Guided by its corporate philosophy, “Pursue Excellence and Deliver Health,” Getein places innovation and quality at the heart of its mission. The company invests 20–30% of its annual profit in research and development, supported by over 400 scientists among its 1,700 employees. This dedication has led to the creation of over 50 fluorescence immunochromatography test kits addressing cardiovascular, renal, infectious, and metabolic diseases. Getein is recognized as a leader in the POCT field in China, with its cardiac diagnostic products ranking among the country’s top market performers.
Getein’s commitment to quality is reinforced by its BSI ISO 13485 Quality Management System and CE certifications, ensuring stability, reliability, and regulatory compliance. The company serves more than 30,000 hospitals in China and numerous healthcare institutions worldwide. With 35 subsidiaries spanning the United States, India, and multiple regions across China, Getein has built an extensive international network reaching over 120 countries.
Beyond technology, Getein emphasizes human wellbeing as the driving force of its growth. Through continuous innovation, global partnerships, and customer-focused solutions, the company strives to become a world-class, research-driven biotechnology enterprise dedicated to advancing healthcare and improving lives across the globe.
_07f78df23886bac97bf1d7a1356ce7a3.jpeg)
